Targeted Medical Pharma, Inc.
TRGM
$0.00
$0.000.00%
| 12/31/2015 | 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | |
|---|---|---|---|---|---|
| Revenue | -26.03% | -35.30% | -37.84% | -25.35% | -25.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -26.03% | -35.30% | -37.84% | -25.35% | -25.57% |
| Cost of Revenue | -5.45% | -2.33% | -7.93% | -16.69% | -25.85% |
| Gross Profit | -35.35% | -47.79% | -49.14% | -29.24% | -25.44% |
| SG&A Expenses | -31.37% | -21.14% | -19.67% | -23.46% | -24.80% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -26.45% | -18.11% | -18.14% | -22.71% | -25.15% |
| Operating Income | 27.59% | -79.02% | -72.94% | 16.52% | 23.97% |
| Income Before Tax | 19.90% | -113.48% | -84.74% | -9.62% | -4.32% |
| Income Tax Expenses | -- | -100.00% | -100.00% | -98.89% | -98.84% |
| Earnings from Continuing Operations | 21.25% | -106.14% | -80.01% | 54.20% | 58.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.85% | -106.14% | -80.01% | 54.20% | 58.29% |
| EBIT | 27.59% | -79.02% | -72.94% | 16.52% | 23.97% |
| EBITDA | 24.87% | -121.44% | -98.81% | 17.05% | 26.90% |
| EPS Basic | 23.54% | -104.87% | -67.42% | 59.39% | 63.05% |
| Normalized Basic EPS | 26.35% | -107.96% | -99.07% | -6.18% | -3.78% |
| EPS Diluted | 23.54% | -104.87% | -67.42% | 59.39% | 63.05% |
| Normalized Diluted EPS | 26.35% | -107.96% | -99.07% | -6.18% | -3.78% |
| Average Basic Shares Outstanding | 3.16% | 3.88% | 5.64% | 8.35% | 10.73% |
| Average Diluted Shares Outstanding | 3.16% | 3.88% | 5.64% | 8.35% | 10.73% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
